Femasys reports Q3 EPS (24c), consensus (20c)

Reports Q3 revenue $554,908, consensus $650k. “We continue to achieve significant commercial milestones with regard to our FemaSeed first-line infertility treatment and its supporting FemVue product. Notably, in 3Q we began commercialization of FemaSeed in the U.S., including a high-profile conglomerate, as well as in Europe with two partners in Spain. We look forward to collaborating with our expanding group of partners as we bring our next generation advancements to women,” said Femasys (FEMY)’ CEO Kathy Lee-Sepsick.